Processa Pharmaceuticals, Inc. (PCSA) Investor Relations Documents

Processa Pharmaceuticals, Inc. (PCSA) investor relations documents from the company's IR site: 12 presentations, 28 press releases; latest deck 2026-07-28. Read in-app with summaries. First-party data.

Presentation: Processa acquires Vidya Therapeutics for $200M, gaining a BTK inhibitor (VT-7208) with Phase 1 data and runway into H2 2029.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-07-29Press releasePROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRE
2026-07-29Press releasePROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRE
2026-07-28PresentationPresentation
2026-01-12Press releaseProcessa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
2026-01-12Press releaseProcessa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
2026-01-05Press releaseProcessa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Canc
2026-01-05Press releaseProcessa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Canc
2025-12-17Press releaseProcessa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
2025-12-17Press releaseProcessa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
2025-11-05Press releaseProcessa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 202
2025-11-05Press releaseProcessa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 202
2025-08-07Press releaseProcessa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
2025-08-07Press releaseProcessa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
2025-07-01Press releaseProcessa Pharmaceuticals Provides Portfolio and Business Update
2025-07-01Press releaseProcessa Pharmaceuticals Provides Portfolio and Business Update
2025-06-17Press releaseProcessa Pharmaceuticals Announces Pricing of $7 Million Public Offering
2025-06-17Press releaseProcessa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastr
2025-06-17Press releaseProcessa Pharmaceuticals Announces Pricing of $7 Million Public Offering
2025-06-17Press releaseProcessa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastr
2025-06-13Press releaseProcessa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
2025-06-13Press releaseProcessa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
2025-03-27PresentationDownload Presentation
2025-02-11Presentationhttps://d1io3yog0oux5.cloudfront.net/_a67d450d2acc59dd775509682ce34f1e/processapharmaceuticals/db/1085/10322/pdf/Processa+General+Investor+Presentation+02112025+Final.pdf
2025-01-27Press releaseProcessa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
2024-10-30Press releaseProcessa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results
2024-10-30Press releaseProcessa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results
2024-10-30Press releasePDF
2024-10-30Press releaseEarnings Release
2024-08-28Press releasePDF
2024-08-26Presentationhttps://d1io3yog0oux5.cloudfront.net/_a67d450d2acc59dd775509682ce34f1e/processapharmaceuticals/db/1085/10317/pdf/Processa+General+Investor+Presentation+August+2024.pdf
2024-04-03Presentationhttps://d1io3yog0oux5.cloudfront.net/_a67d450d2acc59dd775509682ce34f1e/processapharmaceuticals/db/1085/10300/pdf/Processa+General+Investor+Presentation+03282024+Final+%28003%29.pdf
2024-02-20Presentationhttps://d1io3yog0oux5.cloudfront.net/_a67d450d2acc59dd775509682ce34f1e/processapharmaceuticals/db/1085/10296/pdf/Processa+General+Investor+Presentation+2-19-24.pdf
2024-01-11Presentationhttps://d1io3yog0oux5.cloudfront.net/_a67d450d2acc59dd775509682ce34f1e/processapharmaceuticals/db/1085/10293/pdf/Processa+General+Investor+Presentation+01082024+Final+.pdf
2023-12-05Presentationhttps://d1io3yog0oux5.cloudfront.net/_a67d450d2acc59dd775509682ce34f1e/processapharmaceuticals/db/1085/10289/pdf/Processa+Pharmaceuticals+MedInvest+December+2023_David+Young_Final_12052023.pdf
2023-11-16Presentationhttps://d1io3yog0oux5.cloudfront.net/_a67d450d2acc59dd775509682ce34f1e/processapharmaceuticals/db/1085/10286/pdf/20th+Orphan+Drugs+%26+Rare+Disease+November+16+2023+Boston_Final_David+Young.pdf
2023-11-10Presentationhttps://d1io3yog0oux5.cloudfront.net/_a67d450d2acc59dd775509682ce34f1e/processapharmaceuticals/db/1085/10282/pdf/Processa+Corporate+Presentation+20231108.pdf
2023-06-16Presentationhttps://d1io3yog0oux5.cloudfront.net/_a67d450d2acc59dd775509682ce34f1e/processapharmaceuticals/db/1085/10268/pdf/Processa+Pharmaceuticals+MedInvest+June+21+2023_David+Young.pdf
2023-03-30Press releasePDF
2023-03-30Press releaseEarnings Release
2022-11-08Earnings deckEarnings Presentation

PCSA overview · PCSA earnings · PCSA financials · PCSA KPIs · PCSA ownership · PCSA peers · PCSA filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.